First-in-class treatment to delay onset of type 1 diabetes

Teplizumab's ability to delay stage 3 type 1 diabetes onset by preserving beta cell function marks a significant advancement in managing the disease. This breakthrough offers hope for improved patient outcomes, potentially changing the treatment landscape for type 1 diabetes and enhancing clinical practice by providing a novel therapeutic option.